Aclaris Other Liab vs Net Working Capital Analysis
ACRS Stock | USD 1.20 0.01 0.84% |
Aclaris Therapeutics financial indicator trend analysis is way more than just evaluating Aclaris Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Aclaris Therapeutics is a good investment. Please check the relationship between Aclaris Therapeutics Other Liab and its Net Working Capital accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aclaris Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Aclaris Stock please use our How to Invest in Aclaris Therapeutics guide.
Other Liab vs Net Working Capital
Other Liab vs Net Working Capital Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Aclaris Therapeutics Other Liab account and Net Working Capital. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Aclaris Therapeutics' Other Liab and Net Working Capital is -0.23. Overlapping area represents the amount of variation of Other Liab that can explain the historical movement of Net Working Capital in the same time period over historical financial statements of Aclaris Therapeutics, assuming nothing else is changed. The correlation between historical values of Aclaris Therapeutics' Other Liab and Net Working Capital is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Liab of Aclaris Therapeutics are associated (or correlated) with its Net Working Capital. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Working Capital has no effect on the direction of Other Liab i.e., Aclaris Therapeutics' Other Liab and Net Working Capital go up and down completely randomly.
Correlation Coefficient | -0.23 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Other Liab
Net Working Capital
Most indicators from Aclaris Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Aclaris Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aclaris Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Aclaris Stock please use our How to Invest in Aclaris Therapeutics guide.Discontinued Operations is likely to gain to about 167.8 K in 2024, whereas Selling General Administrative is likely to drop slightly above 21.3 M in 2024.
Aclaris Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Aclaris Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Aclaris Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 98.3M | 70.8M | 251.2M | 254.6M | 197.4M | 169.3M | |
Other Current Liab | 12.0M | 4.2M | 3.1M | 2.2M | 10.9M | 4.4M | |
Total Current Liabilities | 22.4M | 14.9M | 22.9M | 21.9M | 31.0M | 16.3M | |
Total Stockholder Equity | 69.9M | 37.7M | 197.3M | 197.6M | 157.2M | 133.2M | |
Other Liab | 2.4M | 7.6M | 28.8M | 33.5M | 38.5M | 40.4M | |
Property Plant And Equipment Net | 2.5M | 1.7M | 1.3M | 1.1M | 1.6M | 1.6M | |
Net Debt | (35.3M) | (42.9M) | (26.7M) | (44.6M) | (39.5M) | (41.4M) | |
Retained Earnings | (453.5M) | (504.5M) | (595.4M) | (682.3M) | (770.8M) | (732.3M) | |
Accounts Payable | 9.9M | 5.3M | 10.0M | 10.4M | 8.9M | 7.2M | |
Cash | 35.9M | 54.1M | 27.3M | 45.3M | 39.9M | 52.9M | |
Non Current Assets Total | 14.5M | 13.3M | 46.2M | 23.0M | 68.5M | 72.0M | |
Cash And Short Term Investments | 75.0M | 54.1M | 225.7M | 229.8M | 119.1M | 137.6M | |
Common Stock Shares Outstanding | 41.3M | 42.5M | 56.7M | 65.2M | 69.8M | 38.5M | |
Short Term Investments | 39.1M | 32.1M | 164.1M | 172.3M | 79.2M | 96.3M | |
Liabilities And Stockholders Equity | 98.3M | 70.8M | 251.2M | 254.6M | 197.4M | 169.3M | |
Non Current Liabilities Total | 6.0M | 18.3M | 30.9M | 35.0M | 9.3M | 8.8M | |
Other Current Assets | 3.1M | 2.6M | 13.0M | 13.5M | 9.5M | 5.7M | |
Other Stockholder Equity | 523.5M | 542.3M | 793.0M | 880.8M | 928.1M | 495.6M | |
Total Liab | 28.4M | 33.1M | 53.9M | 57.0M | 40.2M | 36.1M | |
Property Plant And Equipment Gross | 2.5M | 1.7M | 4.7M | 5.1M | 5.8M | 6.1M | |
Total Current Assets | 83.8M | 57.5M | 205.0M | 231.6M | 128.9M | 139.1M | |
Accumulated Other Comprehensive Income | (66K) | (94K) | (224K) | (897K) | (106K) | (111.3K) | |
Property Plant Equipment | 7.2M | 1.7M | 1.3M | 1.1M | 1.3M | 1.9M | |
Net Tangible Assets | 62.7M | 30.5M | 190.3M | 190.6M | 219.2M | 135.0M | |
Non Currrent Assets Other | 4.8M | 4.5M | 3.6M | (630K) | 1.7M | 1.8M | |
Other Assets | 92K | 4.5M | 251.2M | 1.7M | 2.0M | 1.9M | |
Net Receivables | 704K | 772K | 623K | 484K | 298K | 283.1K | |
Retained Earnings Total Equity | (453.5M) | (504.5M) | (595.4M) | (682.3M) | (614.1M) | (583.4M) | |
Capital Surpluse | 523.5M | 542.3M | 793.0M | 880.8M | 1.0B | 553.9M | |
Inventory | 791K | 5.0M | (34.2M) | (12.2M) | (11.0M) | (10.5M) | |
Intangible Assets | 7.2M | 7.1M | 7.0M | 7.0M | 269K | 255.6K | |
Non Current Liabilities Other | 5.4M | 7.2M | 30.6M | 34.7M | 9.3M | 13.1M | |
Short Long Term Debt Total | 637K | 11.3M | 693K | 684K | 426K | 404.7K | |
Capital Lease Obligations | 637K | 603K | 693K | 684K | 426K | 594.9K | |
Net Invested Capital | 69.9M | 48.3M | 197.3M | 197.6M | 157.2M | 130.4M | |
Net Working Capital | 61.4M | 42.6M | 182.1M | 209.6M | 97.9M | 106.7M |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Aclaris Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Aclaris Therapeutics' short interest history, or implied volatility extrapolated from Aclaris Therapeutics options trading.
Pair Trading with Aclaris Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aclaris Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aclaris Therapeutics will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Aclaris Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aclaris Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aclaris Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aclaris Therapeutics to buy it.
The correlation of Aclaris Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aclaris Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aclaris Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aclaris Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aclaris Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Aclaris Stock please use our How to Invest in Aclaris Therapeutics guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Complementary Tools for Aclaris Stock analysis
When running Aclaris Therapeutics' price analysis, check to measure Aclaris Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aclaris Therapeutics is operating at the current time. Most of Aclaris Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aclaris Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aclaris Therapeutics' price. Additionally, you may evaluate how the addition of Aclaris Therapeutics to your portfolios can decrease your overall portfolio volatility.
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |
Is Aclaris Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aclaris Therapeutics. If investors know Aclaris will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aclaris Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.27) | Revenue Per Share 0.448 | Quarterly Revenue Growth 1.266 | Return On Assets (0.33) | Return On Equity (0.50) |
The market value of Aclaris Therapeutics is measured differently than its book value, which is the value of Aclaris that is recorded on the company's balance sheet. Investors also form their own opinion of Aclaris Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aclaris Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aclaris Therapeutics' market value can be influenced by many factors that don't directly affect Aclaris Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aclaris Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aclaris Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aclaris Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.